Active, Not Recruiting
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
NCT04786028
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- Cross Cancer Institute Edmonton, Alberta, Canada
- Nova Scotia Health - QEII Health Sciences Centre Halifax, Nova Scotia, Canada
- Hamilton Health Sciences Centre Hamilton, Ontario, Canada
- The Ottawa Hospital General Campus Ottawa, Ontario, Canada